Gene Biotherapeutics, Inc. (CRXM) Research

Gene Biotherapeutics, Inc. is a biotechnology company in the clinical development stage, dedicated to researching and bringing to market angiogenic gene therapy treatments for cardiovascular conditions across the United States. Its primary investigational compound, Generx, an angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials. Generx aims to offer a potential treatment for individuals suffering from myocardial ischemia and severe, intractable angina, typically caused by advanced coronary artery disease. Furthermore, the company is exploring Generx's potential for other therapeutic applications related to ischemia affecting both the cardiovascular and cerebral systems. For the production of its Generx angiogenic gene therapy during these pivotal Phase 3 evaluations, Gene Biotherapeutics has established a manufacturing partnership with Fujifilm Diosynth Biotechnologies. Founded in 2003, the company is headquartered in San Diego, California. It officially rebranded as Gene Biotherapeutics, Inc. in January 2018, having previously operated under the name Taxus Cardium Pharmaceuticals Group, Inc.

Open Gene Biotherapeutics, Inc. (CRXM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.